Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 53
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Browne, Elisse C. and Abbott, Belinda M. 2016. Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting. European Journal of Medicinal Chemistry,

    Buendia, Izaskun Michalska, Patrycja Navarro, Elisa Gameiro, Isabel Egea, Javier and León, Rafael 2016. Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacology & Therapeutics, Vol. 157, p. 84.

    Qiu, Hui Li, Ji-huang Yin, Su-bing Ke, Jiang-qiong Qiu, Chang-lin and Zheng, Guo-qing 2016. Dihuang Yinzi, a Classical Chinese Herbal Prescription, for Amyotrophic Lateral Sclerosis. Medicine, Vol. 95, Issue. 14, p. e3324.

    Riesberg, Lisa A. Weed, Stephanie A. McDonald, Thomas L. Eckerson, Joan M. and Drescher, Kristen M. 2016. Beyond muscles: The untapped potential of creatine. International Immunopharmacology, Vol. 37, p. 31.

    Abdul Wahid, S Fadilah Law, Zhe Kang Lai, Nai Ming Ismail, Nor Azimah Azman Ali, Raymond and Abdul Wahid, S Fadilah 2015. Cochrane Database of Systematic Reviews.

    Clark, Rosemary Blizzard, Catherine and Dickson, Tracey 2015. Inhibitory dysfunction in amyotrophic lateral sclerosis: future therapeutic opportunities. Neurodegenerative Disease Management, Vol. 5, Issue. 6, p. 511.

    Estevez, A. Y. DeCoteau, W. E. Heckman, K. L. and Erlichman, J. S. 2015. Oxidative Stress: Diagnostics, Prevention, and Therapy Volume 2.

    Karademir, Betul Corek, Ceyda and Ozer, Nesrin Kartal 2015. Endoplasmic reticulum stress and proteasomal system in amyotrophic lateral sclerosis. Free Radical Biology and Medicine, Vol. 88, p. 42.

    Oh, Seong-il Baek, Soojeong Park, Jin-Seok Piao, Liying Oh, Ki-Wook and Kim, Seung Hyun 2015. Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis. Journal of Clinical Neurology, Vol. 11, Issue. 4, p. 376.

    Gianforcaro, Alexandro and Hamadeh, Mazen J. 2014. Vitamin D as a Potential Therapy in Amyotrophic Lateral Sclerosis. CNS Neuroscience & Therapeutics, Vol. 20, Issue. 2, p. 101.

    Vinay Kumar, Chundi Kumar, K.M. Swetha, Rayapadi Ramaiah, Sudha and Anbarasu, Anand 2014. Protein aggregation due to nsSNP resulting in P56S VABP protein is associated with amyotrophic lateral sclerosis. Journal of Theoretical Biology, Vol. 354, p. 72.

    Zheng, Zhenzhen Guo, Xiaoyan Wei, Qianqian Song, Wei Cao, Bei Huang, Rui Ou, Ruwei Chen, Xueping and Shang, Huifang 2014. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metabolic Brain Disease, Vol. 29, Issue. 3, p. 771.

    Breuer, M.E. Koopman, W.J. Koene, S. Nooteboom, M. Rodenburg, R.J. Willems, P.H. and Smeitink, J.A.M. 2013. The role of mitochondrial OXPHOS dysfunction in the development of neurologic diseases. Neurobiology of Disease, Vol. 51, p. 27.

    Cardona-Rossinyol, Andrea Mir, Margalida Caraballo-Miralles, Víctor Lladó, Jerònia and Olmos, Gabriel 2013. Neuroprotective Effects of Estradiol on Motoneurons in a Model of Rat Spinal Cord Embryonic Explants. Cellular and Molecular Neurobiology, Vol. 33, Issue. 3, p. 421.

    Breuer, Megan E. Willems, Peter H. G. M. Russel, Frans G. M. Koopman, Werner J. H. and Smeitink, Jan A. M. 2012. Modeling mitochondrial dysfunctions in the brain: from mice to men. Journal of Inherited Metabolic Disease, Vol. 35, Issue. 2, p. 193.

    de Almeida, J. P. Lopes Silvestre, R. Pinto, A. C. and de Carvalho, M. 2012. Exercise and amyotrophic lateral sclerosis. Neurological Sciences, Vol. 33, Issue. 1, p. 9.

    DiFebo, Francesca Curti, Daniela Botti, Francesca Biella, Gerardo Bigini, Paolo Mennini, Tiziana and Toselli, Mauro 2012. Neural precursors (NPCs) from adult L967Q mice display early commitment to “in vitro” neuronal differentiation and hyperexcitability. Experimental Neurology, Vol. 236, Issue. 2, p. 307.

    Lee, De-Hyung Gold, Ralf and Linker, Ralf A. 2012. Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters. International Journal of Molecular Sciences, Vol. 13, Issue. 12, p. 11783.

    Lee, Sungyoub Kim, Yumi Li, Endan and Park, Seungjoon 2012. Ghrelin Protects Spinal Cord Motoneurons Against Chronic Glutamate Excitotoxicity by Inhibiting Microglial Activation. The Korean Journal of Physiology & Pharmacology, Vol. 16, Issue. 1, p. 43.

    Pastula, Daniel M Moore, Dan H Bedlack, Richard S and Pastula, Daniel M 2012. Cochrane Database of Systematic Reviews.


Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment

  • Emily F. Goodall (a1) and Karen E. Morrison (a1)
  • DOI:
  • Published online: 24 May 2006

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterised by loss of motor neurons. The cause of disease is unknown other than in the rare cases of familial disease arising from mutations in the superoxide dismutase 1 gene. Many theories for pathogenesis have been proposed – including oxidative stress, excitotoxicity, mitochondrial dysfunction and abnormal protein aggregation – based on studies of human post mortem tissue, research on animal models, and in vitro work. Here we review the evidence for the main pathogenic mechanisms and outline how they might interact to cause motor neuron death. Clinical trials have as yet failed to identify any truly effective therapies in ALS, with only riluzole providing a modest improvement in survival. Ongoing trials are exploring the value of antiglutamatergic agents, including the cephalosporin antibiotic ceftriaxone, as well as antioxidants, mitochondrial enhancers and anti-apoptotic drugs. It is likely that effective therapy will involve combinations of agents acting on different mechanisms. Gene therapy with neurotrophic factors will soon be in clinical trials, while work on stem cell therapy remains preclinical. In addition to finding effective therapies, research also needs to identify early disease markers because therapy is likely to be of most benefit when given early in the course of disease.

Corresponding author
Division of Neurosciences, University of Birmingham, Edgbaston, Birmingham, B152TT, UK. Tel: +44 (0)121 414 3943; Fax: +44 (0)121 414 4509; E-mail:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *